SCHEMBL22043300

SCHEMBL22043300

C=c1cc(C)c(=C)c2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.42
CYP2A6 P11509 5/20 0.37
ALDH1A1 P00352 3/20 0.36
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 2/20 0.35
ACHE P22303 1/20 0.35
PKM P14618 1/20 0.33
CYP2C19 P33261 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
BACE1 P56817 1/20 0.32
ALOX15 P16050 1/20 0.32
ATM Q13315 1/20 0.32
NQO2 P16083 2/20 0.31
KDM4E B2RXH2 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
NPFFR1 Q9GZQ6 1/20 0.31
NPFFR2 Q9Y5X5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2522240 0.69 ALDH1A1 (0.41) CYP1A2CYP2A6ALDH1A1TSHRHPGD
SCHEMBL19427080 0.67 ALDH1A1 (0.42) CYP1A2CYP2A6ALDH1A1TSHRACHE
SCHEMBL29419432 0.67 CYP2A6 (0.40) CYP1A2CYP2A6ALDH1A1TSHRHPGD
SCHEMBL9816096 0.67 CYP2A6 (0.40) CYP1A2CYP2A6ALDH1A1TSHRHPGD
SCHEMBL21503937 0.67 HPRT1 (0.42) CYP1A2CYP2A6ALDH1A1LMNATSHR
SCHEMBL27270292 0.64 HPRT1 (0.40) CYP1A2CYP2A6ALDH1A1LMNATSHR
SCHEMBL18457226 0.62 CYP1A2 (0.36) CYP1A2CYP2A6ALDH1A1LMNATSHR
SCHEMBL17533953 0.60 CYP2A6 (0.37) CYP1A2CYP2A6ALDH1A1TSHRHPGD
SCHEMBL29447796 0.60 CYP1A2 (1.00) CYP1A2CYP2A6ALDH1A1HTTLMNA
SCHEMBL161370 0.60 CYP1A2 (1.00) CYP1A2CYP2A6ALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020112672-A1 BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-06-04 WO disclosed